Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHOC 2022 | GvHD prophylaxis with post-transplant cyclophosphamide

Arnon Nagler • 29 Sep 2022
EHOC 2022
Leukemia Cyclophosphamide

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the impact of post-transplant cyclophosphamide prophylaxis on graft-versus-host disease (GvHD) in haploidentical transplantation. Prof. Nagler first highlights the importance of post-transplant cyclophosphamide, and then explains how the safety and efficacy of transplant have improved with the use of this agent. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals